Autumn and winter influenza is on the rise; YSB (09885) sees an urgent demand window for anti-influenza products.
Pharmaceutical distribution platforms outside hospitals, represented by YSB (09885), occupy this segment. They connect pharmaceutical companies and distributors upstream and serve hundreds of thousands of grassroots pharmacies and clinics downstream, meeting procurement demand through both self-operated and platform channels.
Since November, influenza activity has continued to rise. According to the weekly influenza surveillance report of the Chinese Center for Disease Control and Prevention, in week 43 (October 19-25), 145 influenza-like illness outbreaks were reported nationwide, about 5.2 times the 28 outbreaks in the previous week; by week 45, the positivity rate of influenza-like illness samples from outpatient and emergency departments rose from 14.7% to 18.8%. Southern provinces are at a moderate epidemic level, while northern provinces remain at a low epidemic level but have shown a recent upward trend.
The earlier arrival of the flu season has already transmitted to out-of-hospital channels. According to Zhongkang data, in weeks 43 and 44, the national pharmacy viral cold medication sales index rose by 7.28 points and 15.89 points respectively month-on-month, and average daily sales per store increased by 3.6% and 5.7% month-on-month, respectively, lower than the 25.1% and 54.9% in the same period of 2025.
At the category level, cold medications already showed an inflection point in the third quarter. According to Zhongkang data, retail sales of cold/heat-clearing, cough and expectorant and antiasthmatic, and oral and throat categories turned from declines of 27.6%, 18.5%, and 6.8% in the first quarter to growth of 11.7%, 7.8%, and 5.0% in the third quarter, totaling about RMB47.4 billion in the first three quarters. During the same period, average customer transaction value per store fell to RMB64, down 4% year-on-year, and there was no concentrated stockpiling of medicines at the terminal level.
Although there was no concentrated stockpiling on the consumer side, inventory pressure has fallen on pharmacies. According to Zhongkang data, in the third quarter, average orders per store for cold medications were 184 orders/store/month, ranking first among all categories and making it a traffic-entry category for grassroots pharmacies; flu-season stocking tests the supply stability and replenishment speed of commonly used medicines. Out-of-hospital pharmaceutical distribution platforms represented by YSB (09885) sit in this segment, connecting pharmaceutical companies and distributors upstream and serving hundreds of thousands of grassroots pharmacies and clinics downstream, undertaking procurement demand through both self-operated and platform channels; its interim report shows that its platform had about 460,000 monthly active buyers and about 4.3 million monthly sellable SKUs.
From an industry perspective, the total number of pharmacies is declining, and per-store efficiency has become the focus of operations. Whether the supply side can stably provide high-gross-margin categories and compliance capabilities directly affects the operating space of individual stores. Some analysts believe that the incremental demand in this flu season is concentrated in antiviral chemical drugs, pathogen testing, and pediatric dosage forms, and platforms with category organization capabilities are better positioned to capture it. Based on 2025 net profit attributable to parent of RMB153 million, YSB's current market capitalization is about HK$2.1 billion, corresponding to a price-to-earnings ratio of about 14 times. The actual intensity and duration of the flu season remain variables determining the height of demand and warrant attention.
Related Articles

Report: AI advertising giant AppLovin (APP.US) in talks to acquire peer Criteo (CRTO.US), possibly aiming to expand in retail media

The United States tightens overseas AI chip controls. Jefferies Financial Group Inc.: Approximately US$44 billion of NVIDIA Corporation's (NVDA.US) 2027 revenue may be affected.

Sealand: Aluminum prices rise, performance surges, maintain BUY rating on CHINAHONGQIAO (01378)
Report: AI advertising giant AppLovin (APP.US) in talks to acquire peer Criteo (CRTO.US), possibly aiming to expand in retail media

The United States tightens overseas AI chip controls. Jefferies Financial Group Inc.: Approximately US$44 billion of NVIDIA Corporation's (NVDA.US) 2027 revenue may be affected.

Sealand: Aluminum prices rise, performance surges, maintain BUY rating on CHINAHONGQIAO (01378)






